Brainsway

Brainsway Ltd. is a commercial stage medical device company, which focuses on the development and sale of non-invasive neuromodulation products using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The Deep TMS uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. The company was founded by Avner Hagai, Yiftach Roth, Abraham Zangen, and David Zacut on November 7, 2006 and is headquartered in Jerusalem, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Brainsway Ltd. engages in the development and sale of non-invasive neurostimulation treatments using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The Deep TMS uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. The company was founded by Avner Hagai, Yiftach Roth, Abraham Zangen, and David Zacut on November 7, 2006 and is headquartered in Jerusalem, Israel.

BURLINGTON, Mass. and JERUSALEM, Aug. 17, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will host a key opinion leader (KOL) webinar on its Deep TMS™ therapy for treating mental health disorders on Tuesday, August 31, 2021, at 11am Eastern Time.

BrainsWay Hosting Key Opinion Leader Webinar on its Deep TMS™ Therapy for Treating Mental Health Disorders

BrainsWay Ltd.'s (BWAY) CEO Christopher von Jako on Q2 2021 Results - Earnings Call Transcript

Strong Revenue Growth of 45% Year-over-Year in Q2 2021

BrainsWay Reports Second Quarter 2021 Financial Results and Operational Highlights

CRESSKILL, N.J. and JERUSALEM, July 28, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its second quarter 2021 financial results as well as operational highlights before the open of the U.S. financial markets on Wednesday, August 11, 2021. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

BrainsWay to Report Second Quarter 2021 Financial Results on August 11, 2021

Engaging event for local mental health clinicians to learn more about BrainsWay's Deep Transcranial Magnetic Stimulation (Deep TMS) helmet, cleared to treat MDD and OCD, currently available in Charlotte.

MindPath Care Centers Hosts Open House in Charlotte to Introduce FDA-Cleared Deep TMS™ Treatment for Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD)

CRESSKILL, N.J. and JERUSALEM, Israel, June 07, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd . (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments of mental health disorders, today announced the Company will participate in the upcoming global medical conferences:

BrainsWay to Present at Clinical TMS Society Annual Meeting and Psych Congress Elevate

In the past 12 months BrainsWay has received FDA clearance for the Theta Burst protocol and assisting smoking cessation as well as positive coverage policies for OCD. Insurance coverage for OCD strengthens BrainsWay's position as the TMS market leader and confirms the potential of TMS outside of treating MDD.

BrainsWay: Still Undervalued (Still)

BrainsWay (BWAY) has moved higher as of late, but there could definitely be trouble on the horizon for this company

BrainsWay (BWAY) is in Overbought Territory: What's Next?

Brainsway Ltd. Sponsored ADR (BWAY) saw its shares surge in the last session with trading volume being higher than average.

Brainsway Ltd. Sponsored ADR (BWAY) Moves 10.6% Higher: Will This Strength Last?

The stock price of Brainsway (NASDAQ: BWAY) increased by over 8% pre-market. This is why it happened.

BWAY Stock Price: Over 8% Increase Pre-Market Explanation

CRESSKILL, N.J. and JERUSALEM, May 24, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that Centene Corporation has published a positive coverage policy for Deep Transcranial Magnetic Stimulation (TMS) treatment of obsessive-compulsive disorder (OCD) using the BrainsWay Deep TMS™ system. Centene provides coverage to about 25 million members in all 50 states, including Medicaid and Medicare members, as well as to individuals and families served by the Health Insurance Marketplace, the TRICARE program, and commercial insurance.

BrainsWay Announces First of its Kind Positive Coverage Policy by Centene for the Treatment of OCD Utilizing Deep TMS™

BrainsWay Ltd. (BWAY) CEO Chris von Jako on Q1 2021 Results - Earnings Call Transcript

Strong Revenue Growth of 47% Year-over-Year in Q1 2021

BrainsWay Reports First Quarter 2021 Financial Results and Operational Highlights

CRESSKILL, N.J. and JERUSALEM, May 19, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disorders, today announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will present at the Oppenheimer MedTech, Tools & Diagnostics Summit on May 26, 2021. The Company will also host one-on-one investor meetings at the conference.

BrainsWay to Present at the Oppenheimer MedTech, Tools & Diagnostics Summit

BrainsWay (BWAY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy BrainsWay (BWAY) Ahead of Earnings?

CRESSKILL, N.J. and JERUSALEM, Israel, May 06, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disorders, today announced that it will report its first quarter 2021 financial results as well as operational highlights before the open of the U.S. financial markets on Thursday, May 20, 2021. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

BrainsWay to Report First Quarter 2021 Financial Results on May 20, 2021

CRESSKILL, N.J. and JERUSALEM, May 05, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of R. Scott Areglado as Senior Vice President and Chief Financial Officer effective today.

BrainsWay Announces Appointment of R. Scott Areglado as Senior Vice President and Chief Financial Officer

The Sweepstakes, demonstrating how Deep Transcranial Magnetic Stimulation (Deep TMS) can fit into an average day, offers participants a chance to be one of 20 winners who will receive a curated self-care package The Sweepstakes, demonstrating how Deep Transcranial Magnetic Stimulation (Deep TMS) can fit into an average day, offers participants a chance to be one of 20 winners who will receive a curated self-care package

BrainsWay Announces Social Media Sweepstakes to Celebrate Mental Health Awareness Month

Patients in areas across the country now have access to Deep Transcranial Magnetic Stimulation (Deep TMS) therapy as an aid for short-term smoking cessation Patients in areas across the country now have access to Deep Transcranial Magnetic Stimulation (Deep TMS) therapy as an aid for short-term smoking cessation

BrainsWay Announces Launch of Noninvasive Treatment for Smoking Addiction to U.S. Providers

Brainsway Ltd. Sponsored ADR (BWAY) witnessed a jump in share price last session on above-average trading volume.

Strength Seen in Brainsway Ltd. Sponsored ADR (BWAY): Can Its 7.3% Jump Turn into More Strength?

The FDA has granted 501(k) clearance for BrainsWay Ltd's (NASDAQ: BWAY) Theta Burst three-minute protocol utilizing its Deep Transcranial Magnetic Stimulation (Deep TMS) system for major depressive disorder (MDD). "Many patients and providers can benefit from significantly shorter treatment sessions, and our Theta Burst protocol can provide these patients with another option to manage their treatment-resistant depression," said Hadar Levy, Senior Vice President and General Manager.

BrainsWay Stock Is Trading Higher After FDA OK's Three-Minute Theta Burst Treatment Protocol For Major Depressive Disorder

The stock price of Brainsway (NASDAQ: BWAY) increased by over 14% pre-market. This is why it happened.

BWAY Stock: Over 14% Increase Pre-Market Explanation

Shorter Protocol Further Expands Access to Care Shorter Protocol Further Expands Access to Care

BrainsWay Receives FDA Clearance for Three-Minute Theta Burst Treatment Protocol for Major Depressive Disorder

The FDA cleared technology is a noninvasive treatment for depression, OCD, and smoking addiction The FDA cleared technology is a noninvasive treatment for depression, OCD, and smoking addiction

BrainsWay Announces 100,000 Patients Treated with Deep Transcranial Magnetic Stimulation (Deep TMS)

BrainsWay's (BWAY) CEO Christopher von Jako on Q4 2020 Results - Earnings Call Transcript

News for Brainsway Stock (BWAY)